

Yves Allenbach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3921068/publications.pdf>

Version: 2024-02-01

78
papers

4,948
citations

126907

33
h-index

102487

66
g-index

82
all docs

82
docs citations

82
times ranked

4340
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey"™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e30-e30. | 0.9 | 11 |
| 2 | 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 114-116. | 1.6 | 13 |
| 3 | Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96. | 1.6 | 1 |
| 4 | Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up. <i>Journal of Translational Autoimmunity</i> , 2022, 5, 100148. | 4.0 | 4 |
| 5 | Peripheral neuropathy and livedoid vasculopathy. <i>Journal of Neurology</i> , 2022, 269, 3779-3788. | 3.6 | 6 |
| 6 | Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive interstitial lung disease. <i>European Respiratory Journal</i> , 2022, 59, 2102968. | 6.7 | 8 |
| 7 | Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. , 2022, 10, e004699. | | 29 |
| 8 | 256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021. <i>Neuromuscular Disorders</i> , 2022, 32, 594-608. | 0.6 | 13 |
| 9 | Endoplasmic reticulum"stress and unfolded protein response"activation in immune-mediated necrotizing myopathy. <i>Brain Pathology</i> , 2022, 32, . | 4.1 | 7 |
| 10 | EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48. | 0.9 | 153 |
| 11 | Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. <i>Joint Bone Spine</i> . 2020;87:191"93. <i>Joint Bone Spine</i> , 2021, 88, 105074. | 1.6 | 5 |
| 12 | Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. <i>European Radiology</i> , 2021, 31, 4264-4276. | 4.5 | 19 |
| 13 | Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. <i>Autoimmunity Reviews</i> , 2021, 20, 102729. | 5.8 | 26 |
| 14 | Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 85-112. | 9.4 | 50 |
| 15 | Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. <i>Rheumatology</i> , 2021, 60, 5713-5723. | 1.9 | 17 |
| 16 | The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. <i>Autoimmunity Reviews</i> , 2021, 20, 102788. | 5.8 | 17 |
| 17 | The role of interferons type I, II and III in myositis: A review. <i>Brain Pathology</i> , 2021, 31, e12955. | 4.1 | 44 |
| 18 | MRI and muscle imaging for idiopathic inflammatory myopathies. <i>Brain Pathology</i> , 2021, 31, e12954. | 4.1 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | NanoString technology distinguishes anti-TIF1 ^β from anti-Mi2 ⁺ dermatomyositis patients. <i>Brain Pathology</i> , 2021, 31, e12957. | 4.1 | 11 |
| 20 | Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1329. | 6.1 | 64 |
| 21 | Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <i>Thérapie</i> , 2021, 76, 285-295. | 1.0 | 8 |
| 22 | NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. <i>Cells</i> , 2021, 10, 2551. | 4.1 | 8 |
| 23 | 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92. | 0.6 | 148 |
| 24 | Sequestosome 1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies. <i>Brain Pathology</i> , 2020, 30, 261-271. | 4.1 | 42 |
| 25 | Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102465. | 5.8 | 14 |
| 26 | Granulomatosis-associated myositis. <i>Neurology</i> , 2020, 94, e910-e920. | 1.1 | 21 |
| 27 | Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0240711. | 2.5 | 54 |
| 28 | Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1140-1149. | 3.4 | 14 |
| 29 | Immune-mediated necrotizing myopathy: clinical features and pathogenesis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 689-701. | 8.0 | 131 |
| 30 | Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study. <i>Pharmaceuticals</i> , 2020, 13, 317. | 3.8 | 40 |
| 31 | Response to: On using machine learning algorithms to define clinically meaningful patient subgroups TM by Pinal-Fernandez and Mammen. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e130-e130. | 0.9 | 0 |
| 32 | Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. <i>Neurology</i> , 2020, 95, e70-e78. | 1.1 | 142 |
| 33 | Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586. | 5.8 | 80 |
| 34 | Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1437-1440. | 3.4 | 28 |
| 35 | Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. <i>Journal of Autoimmunity</i> , 2020, 111, 102454. | 6.5 | 11 |
| 36 | Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis. <i>Brain Pathology</i> , 2020, 30, 867-876. | 4.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306. | 2.5 | 10 |
| 38 | Title is missing!. , 2020, 15, e0240711. | | 0 |
| 39 | Title is missing!. , 2020, 15, e0240711. | | 0 |
| 40 | Title is missing!. , 2020, 15, e0240711. | | 0 |
| 41 | Title is missing!. , 2020, 15, e0240711. | | 0 |
| 42 | Myocarditis in the Setting of Cancer Therapeutics. Circulation, 2019, 140, 80-91. | 1.6 | 278 |
| 43 | Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain, 2019, 142, e60-e60. | 7.6 | 3 |
| 44 | Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain, 2019, 142, e9-e9. | 7.6 | 1 |
| 45 | Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. Journal of Neuromuscular Diseases, 2019, 6, 99-107. | 2.6 | 7 |
| 46 | Abatacept for Severe Immune Checkpoint Inhibitorâ€‘Associated Myocarditis. New England Journal of Medicine, 2019, 380, 2377-2379. | 27.0 | 296 |
| 47 | PD1 pathway in immune-mediated myopathies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e558. | 6.0 | 42 |
| 48 | Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. Journal of Neuroimmunology, 2019, 332, 212-215. | 2.3 | 13 |
| 49 | The IgG2 Isotype of Antiâ€‘Transcription Intermediary Factor 1 ^{Î²} Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis and Rheumatology, 2019, 71, 1360-1370. | 5.6 | 33 |
| 50 | CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis. Autoimmunity Reviews, 2019, 18, 325-333. | 5.8 | 21 |
| 51 | Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM). European Radiology, 2019, 29, 5139-5147. | 4.5 | 19 |
| 52 | Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Safety, 2019, 42, 813-825. | 3.2 | 78 |
| 53 | Expanding the spectrum of HIV-associated myopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1296-1298. | 1.9 | 7 |
| 54 | Infliximab as effective treatment for aseptic neutrophilic myositis. Neurology, 2019, 93, 1009-1011. | 1.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e523. | 6.0 | 66 |
| 56 | Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy. <i>Journal of Rheumatology</i> , 2019, 46, 623-627. | 2.0 | 36 |
| 57 | Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. <i>Autoimmunity Reviews</i> , 2019, 18, 223-230. | 5.8 | 44 |
| 58 | <i>In vivo</i> pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotizing myopathy. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 131-139. | 0.9 | 97 |
| 59 | Necrosis in anti-SRP and anti-HMGCR myopathies. <i>Neurology</i> , 2018, 90, e507-e517. | 1.1 | 132 |
| 60 | Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1423-1432. | 1.5 | 30 |
| 61 | Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. <i>Joint Bone Spine</i> , 2018, 85, 375-376. | 1.6 | 14 |
| 62 | Immune Checkpoint Inhibitor-Associated Myositis. <i>Circulation</i> , 2018, 138, 743-745. | 1.6 | 139 |
| 63 | Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. <i>Brain</i> , 2018, 141, e81-e81. | 7.6 | 4 |
| 64 | Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. <i>JAMA Neurology</i> , 2018, 75, 1528. | 9.0 | 301 |
| 65 | Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies. <i>Current Rheumatology Reports</i> , 2018, 20, 56. | 4.7 | 10 |
| 66 | Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 11. | 3.3 | 42 |
| 67 | JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. <i>Brain</i> , 2018, 141, 1609-1621. | 7.6 | 169 |
| 68 | Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. <i>Neurology</i> , 2018, 91, e985-e994. | 1.1 | 247 |
| 69 | Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 241-249. | 2.6 | 31 |
| 70 | Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry. <i>PLoS ONE</i> , 2018, 13, e0194593. | 2.5 | 26 |
| 71 | Pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. <i>Annals of Neurology</i> , 2017, 81, 538-548. | 5.3 | 112 |
| 72 | IFN- γ -induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. <i>Acta Neuropathologica</i> , 2017, 134, 655-666. | 7.7 | 78 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Advances in serological diagnostics of inflammatory myopathies. <i>Current Opinion in Neurology</i> , 2016, 29, 662-673. | 3.6 | 96 |
| 74 | Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993. | 5.8 | 105 |
| 75 | Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. <i>American Journal of Pathology</i> , 2016, 186, 691-700. | 3.8 | 78 |
| 76 | Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. <i>Neurology</i> , 2015, 84, 1346-1354. | 1.1 | 90 |
| 77 | Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies. <i>Medicine (United States)</i> , 2014, 93, 150-157. | 1.0 | 235 |
| 78 | Long-term observational study of sporadic inclusion body myositis. <i>Brain</i> , 2011, 134, 3176-3184. | 7.6 | 319 |